The PARC study: A phase I/II study evaluating the safety and activity of Pegylated recombinant human Arginase (BCT-100) Relapsed/refractory Cancers of Children and Young Adults

  • Kirby, Maria L (Primary Chief Investigator (PCI))
  • McCowage, Geoff (Chief Investigator (CI))
  • Ziegler, David (Chief Investigator (CI))
  • Mussai, Francis (Chief Investigator (CI))
  • Strong, Robyn, (Chief Investigator (CI))
  • Jones, Janelle, (Associate Investigator (AI))

Project: Research

Short titlePARC study
StatusActive
Effective start/end date2/04/19 → 31/12/22

Funding

  • The Department of Health (Comm): AUD480,015.00
View all
View less

Keywords

  • cancer chemotherapeutic agents
  • Clinical trial
  • paediatric
  • relapse
  • arginine
  • cancer chemotherapeutic agents
  • Clinical trial
  • paediatric
  • relapse
  • arginine
  • cancer chemotherapeutic agents
  • Clinical trial
  • paediatric
  • relapse
  • arginine